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a b s t r a c t
In the US, rabies lyssavirus (RABV) only circulates in wildlife species and the most significant reservoir
from a public and animal health perspective is the raccoon (Procyon lotor). Management of wildlife rabies
relies principally on oral rabies vaccination (ORV) strategies using vaccine-laden bait delivery to free-
ranging target hosts, in order to reduce the susceptible population to prevent the spread of and eliminate
RABV circulation. Our objective was to evaluate efficacy of the Ontario Rabies Vaccine Bait (ONRAB)
against a lethal RABV challenge in captive raccoons. Sham or live vaccine baits were offered to 50
raccoons and efficacy was evaluated in 46, split into two trials of 17 and 29 raccoons. Raccoons were chal-
lenged with a lethal dose of RABV 180 days post-vaccination and observed for 90 days post-infection.
Raccoon bait interactions were assigned increasing integer scores for approach, oral manipulation, punc-
ture, and consumption behaviors. Higher bait interaction scores were observed in the fall compared to
the spring trial, indicating that more raccoons consumed baits in the fall. Although animal age did not
explain variation in bait interaction scores, the geometric mean rabies virus antibody titers among juve-
nile vaccinates were higher than adults at all pre-challenge time points. The prevented fraction associ-
ated with ONRAB delivery was 0.73 (8/11, 95% CI 0.39–0.94) in the spring trial and 0.91 (21/23, 95% CI
0.72–0.99) in the fall trial. All sham-vaccinated raccoons (12/12) succumbed to rabies infection, in con-
trast to 15% (5/34) mortality among vaccinated raccoons. Our results indicate a high efficacy of ONRAB
bait vaccination in protecting adult and juvenile raccoons against RABV infection for a minimum of six
months. These data complement experimental field trials that have also demonstrated the potential of
ONRAB for the control and prevention of RABV circulation in free-ranging raccoon populations in the US.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
1. Introduction
In the United States (US), rabies lyssavirus (RABV) only circu-
lates in wildlife species and the most significant reservoir from a
public and animal health perspective is the raccoon (Procyon lotor).
The human exposures and animal case burden associated with rac-
coon RABV is due in part to the ubiquitous nature and high popu-
lation densities of this peri-domestic species in suburban and
urban habitats [1–3]. The current enzootic focus of raccoon RABV
extends from a historical area in the southeastern US north to
the border with Canada. Management of wildlife rabies historically
involved population reduction strategies (e.g. culling), but now
focuses on oral rabies vaccination (ORV) strategies to deliver
vaccine-laden baits to free-ranging target hosts, in order to reduce
the susceptible population [4]. The National Rabies Management
Program (NRMP), administered by the US Department of
Agriculture (USDA), Animal and Plant Health Inspection Service,
Wildlife Services program, has the mission to control and eliminate
specific RABV variants circulating in wild carnivores in the US.
Coordinated ORV programs to target raccoons have been opera-
tional since the 1990s [5]. While ORV has been successful in pre-
venting westward spread of raccoon RABV in the US, post-ORV
population immunity levels have averaged 30% across several
years and have led to concern about the ability of current ORV
products to eliminate RABV circulation in raccoons [5].
The Raboral V-RG product (Boehringer Ingelheim Animal
Health, Athens, Georgia, USA) is the only oral rabies vaccine cur-
rently licensed for use with free-ranging raccoons and coyotes
(Canis latrans) in the US [6]. However, another product has shown
promising results for the control of RABV in raccoons and striped
skunks (Mephitis mephitis) in southern Ontario, Canada [7,8]. The
Ontario Rabies Vaccine Bait (ONRAB; Artemis Technologies, Inc.,
https://doi.org/10.1016/j.vaccine.2018.06.052
0264-410X/Published by Elsevier Ltd.
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Guelph, Ontario, Canada) is comprised of a sweet attractant matrix
that coats a blister pack containing a live recombinant human ade-
novirus expressing the RABV glycoprotein [9], and is licensed for
use with free-ranging striped skunks in Canada. One study demon-
strated immunogenicity and efficacy of ONRAB baits for raccoons,
but did not meet prevented fraction standards for animal rabies
vaccines in the US [10].
We conducted a randomized and blind evaluation of the effi-
cacy of ONRAB ultralite baits (ULBs) in protecting raccoons against
lethal RABV infection, to re-assess its potential for meeting efficacy
standards for animal rabies vaccines in the US.
2. Materials and methods
2.1. Animals, housing, and restraint
A total of 65 naïve captive-bred raccoons (19 adult males, 20
adult females, 14 juvenile males, 12 juvenile females) were
obtained from Ruby Fur Farm (New Sharon, Iowa, USA). Animal
use procedures were reviewed and approved by the Institutional
Animal Care and Use Committee of the USDA National Wildlife
Research Center (NWRC) under protocol 2278. The import and
housing of raccoons at the NWRC facility was authorized under Col-
orado Parks and Wildlife permits 14TR2056A1, 15TR2143, and
16TR2143. During quarantine, individual animal health was
inspected by a veterinarian and passive integrated transponders
(PIT tags; Avid Identification System, Inc., Norco, California, USA)
were subcutaneously injected into each raccoon under anesthesia
for unique identification (ID). A total of 50 raccoons (30 adults, 20
juveniles) were randomly assigned to the vaccine efficacy study,
which was conducted as two consecutive trials (trial 1, n = 21,
March 2015–December 2016; trial 2, n = 29, November 2015–
August 2016). At the time of vaccination, juveniles in the first trial
were ten months old and in the second trial were six months old.
A total of 15 raccoons (9 adults, 6 juveniles) were used in a chal-
lenge virus titration study, conducted as two consecutive trials dur-
ing November 2014 (n = 10) and January 2016 (n = 5). All raccoons
were housed in individual elevated pens (1.2  2.4  1.8 m) in an
open-air outdoor building during quarantine and vaccination. Rac-
coonsweremoved to individual pens on concrete (3  3  2.5 m) in
an open-air outdoor building during post-vaccination (pv)monitor-
ing. Raccoons were housed in individual cages (0.7X1X1m) in an
Animal Biosafety Level 2 room during RABV challenge and post-
infection (pi) monitoring. Each pen or cage had a den box attached
to the outer edge, and contained other forms of enrichment.
Raccoons were fed a daily ration of 200 g of Mazuri omnivore diet
(PMI Nutrition International, St. Louis, Missouri, USA) except during
vaccination and were provided water ad libitum. Raccoons were
anesthetized using inhalation delivery of isoflurane gas or intra-
muscular (IM) injection a 5:1 ratio (20 mg/kg and 4 mg/kg respec-
tively) of ketamine (Ketaset; Zoetis, Inc., Florham Park, New
Jersey, USA) to xylazine (AnaSed; Akorn, Inc., Lake Forest, Illinois,
USA) for the purpose of blood sample collection from a jugular vein
and inoculation. For isoflurane anesthesia, induction was accom-
plished by delivery of 5% isoflurane in oxygen at 5L/min in the den
box containing the animal [11]. Upon induction, a conewas then fit-
ted over the oronasal region for maintenance at 2–3% at 1–2 L/min
during sample collection. Upon completion of procedures, animals
were returned to den box for arousal under ambient conditions,
and monitored until bright, alert and responsive to stimuli.
2.2. Challenge virus titration study
A RABV challenge virus was obtained from the USDA Center for
Veterinary Biologics. The 92-5A RABV is a New York City dog vari-
ant that was most recently passaged in red foxes (Vulpes vulpes).
This virus was selected for study because it met regulatory require-
ments for purity, potency, and purpose. The neat titer was 107.9
mouse intracerebral lethal doses per mL (MICLD50/ml). Virus was
diluted using sterile phosphate buffered saline, supplemented with
2% fetal bovine serum (Invitrogen, Carlsbad, California, USA). As
data were not available regarding pathogenicity of this virus for
raccoons, an initial titration trial was designed so that five raccoons
each were randomly assigned, while blocking for sex and age, to
receive a dose of 106.9 or 105.9 MICLD50/mL. In a second trial, five
additional raccoons received the 105.9 MICLD50/mL dose to test
the repeatability of the initial trial outcome at this dose. Baseline
blood samples were collected from each raccoon prior to IM inoc-
ulation with 0.5 mL of diluted RABV into each masseter muscle
(1.0 mL total). Animals were monitored daily, or twice-daily during
the expected clinical period (days 7–35 pi), for 90 days pi. Upon
display of two or more clinical signs of rabies, raccoons were anes-
thetized with an IM injection of ketamine/xylazine. Under heavy
anesthesia, a terminal blood sample was collected prior to intrac-
ardiac administration of pentobarbital sodium and phenytoin
sodium (VetOne Euthanasia Solution; Med-Pharmex, Inc., Pomona,
California, USA). Surviving raccoons were euthanized on or after
day 90 pi. Brainstem and cerebellum tissues were collected post-
mortem from individual raccoons.
2.3. Vaccine immunogenicity and efficacy study
Fifty raccoons were randomly assigned, while blocking for sex
and age, to one of two treatment groups, live or sham, for
presentation of a single ONRAB ULB (lots AdRG1.3 14-01, AdRG1.3
14-01P). Raccoon treatments were assigned by the cooperator
(Artemis), and the NWRC research team was blind to the assign-
ments until the conclusion of each efficacy trial. Food was withheld
from raccoons for 24 h prior to bait offering. A total of 12 raccoons
received a sham bait, and 38 raccoons received a live bait contain-
ing 1.8 mL of vaccine at a titer of 109.6 TCID50/mL during a 24 h
presentation window. Bait offering was monitored using motion-
activated trail cameras (Reconyx Silent Image, Holmen, Wisconsin)
and video cameras (Supercircuits model PC161IR, Supercircuits,
Inc., Austin, Texas, USA; Zodiac model CAMZ836IR, Zodiac Light
Waves Inc., Ontario, Canada; Polaris model EZ-380VF, Polaris
USA, Norcross, Georgia, USA). Plastic sheets were placed under-
neath the elevated cages of each animal prior to bait offering to
collect bait debris and vaccine spillage, and were inspected every
4 hrs to assess bait remains and estimate spillage to the nearest
0.1 mL using a pipette.
Scores were assigned for each raccoon-bait interaction as fol-
lows: (0) animal does not approach bait, (1) animal approaches
bait, but without oral contact, (2) oral manipulation of bait by ani-
mal, but no puncture of blister pack, (3) oral manipulation and
puncture of the blister pack, but incomplete consumption, or (4)
animal consumes entire bait. Camera and video footage were ana-
lyzed post-trial to verify scores.
Baseline blood samples were collected from raccoons prior to
vaccination, and then on days 30, 60, 90, and 176 pv. Raccoons
were challenged on day 180 pv by IM inoculation with 0.5 mL of
diluted RABV into each masseter muscle (1.0 mL total). Animals
in the first trial (n = 17) were inoculated with 106.2 MICLD50/mL
of RABV. Based on results of the first trial, the animals in the second
trial (n = 29) were inoculated with a lower dose of 105.9 MICLD50/
mL. Animals were monitored as described previously, and blood
samples were collected on days 15, 30, and 60 pi. Surviving rac-
coons were euthanized on days 90 or 91 pi. The procedures for
euthanasia and tissue collection were the same as described for
the challenge virus titration study.
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2.4. Detection of rabies virus antigen
Brainstem and cerebellum tissues from individual raccoons
were stored in conical vials on ice packs and submitted the same
day or refrigerated and submitted within 72 h to the Veterinary
Teaching Hospital Diagnostic Lab at Colorado State University for
rabies diagnosis using the direct fluorescent antibody test [12].
2.5. Detection of rabies virus antibodies
Blood samples were centrifuged at 4000g for 15 min and serum
was separated into cryovials. Sera were stored at 80 C until ship-
ment to the Rabies Laboratory at Kansas State University (KSU).
Sera were analyzed to titrate the level of RABV neutralizing anti-
bodies (RVNA) to endpoint by rapid fluorescent focus inhibition
test (RFFIT) [13]. Titers were converted to international units per
mL (IU/mL) by comparison to a positive control standard rabies
immune globulin containing 2 IU/mL. Titers less than 0.1 IU/mL
were considered negative and titers greater than or equal to 0.1
IU/mL were considered RVNA positive. The vaccine efficacy trial
sera were also evaluated for RABV binding antibodies (RVBA) at
KSU by a commercial indirect ELISA (BioRad Platelia Rabies Kit II,
Marnes-la-Coquette, France) using the Bio-Rad Evolis instrument
per the manufacturer’s instructions. Sample test results were
reported in equivalent units per mL (EU/mL) calculated by compar-
ison of the sample optical density against a standard curve of pos-
itive standards supplied in the kit. Sample EU/mL values of less
than or equal to 0.125 EU/mL were considered negative, and values
greater than 0.125 EU/mL were considered RVBA positive.
2.6. Detection of rabies virus RNA
Brainstem tissue from rabid animals was tested by PCR analysis
to confirm a match to the challenge inoculum. RNA extraction,
reverse transcription, amplification, cleanup and sequencing were
performed as previously described [14]. Forward and reverse
sequences were aligned and visually inspected using Sequencher
(Gene Codes Corporation, Ann Arbor, Michigan, USA). Alignment
of consensus sequences and identity comparisons were performed
using BioEdit v.7.2.0. [15].
2.7. Analyses
A generalized linear model was used to analyze the bait interac-
tion score data across 50 raccoons. Bait treatment (live/sham), age
(adult/juvenile), sex (male/female), and trial (one/two) were evalu-
ated as fixed effects in a multivariable model. A multinomial distri-
bution with cumulative logit link function was used to model the
relationship of fixed effects with ascending interaction scores (i.e.,
scale of 0–4). The antibody response data were natural log trans-
formed and checked for normality. The difference in mean antibody
response between adult and juvenile vaccinates across pv time
points was compared by t-test. The pooled variance method was
used for t-tests when the variance of the antibody response was
equal between adult and juvenile raccoons, whereas the Satterth-
waitemethodwas usedwhen the variance of the antibody response
between adult and juvenile raccoons was unequal. The t-test
p-values were adjusted for multiple comparisons (i.e., time points)
using the Holm method [16]. The prevented fraction and 95% exact
confidence intervals from the vaccine efficacy experiments were
calculated from 46 challenged raccoons. A survival analysis was
performed to test for homogeneity in survival curves pi, using a
log-rank test on data stratified by bait treatment and age and the
Šidák correction to adjust for multiple pairwise comparisons. SAS
v.9.4 was used to perform all analyses (SAS Institute, Cary, North
Carolina, USA) and significance was assessed at a = 0.05.
Geometric mean titers (GMT) and 95% confidence intervals
were calculated among juvenile and adult vaccinates at specific
time points. For the purpose of GMT calculations, RVNA titers of
less than 0.1 IU/mL were treated as 0.05 and RVBA titers of less
than or equal to 0.125 EU/mL were treated as 0.063. Also for
GMT calculation purposes, seven vaccinate sera on day 15 pi with
RVBA values exceeding the detection limit (i.e., 20.000 EU/mL)
were coded as 20.000 EU/mL.
3. Results
3.1. Challenge virus titration
Thirteen of 15 naïve challenged raccoons developed rabies, and
sequencing of brain tissue demonstrated 100% identity to the RABV
inoculum. Mortality was 100% and incubation periods were 10–15
days (median: 11 days) for five raccoons inoculated with 106.9
MICLD50, and mortality was 80% with incubation periods of
10–13 days (median: 12 days) for ten raccoons inoculated with
105.9 MICLD50 (Table 1). Clinical signs most commonly included
paresis, ataxia, tremors, and lethargy or irritability. Neither of the
two surviving raccoons presented a terminal RVNA titer at day
90 pi. However, among 12 animals which succumbed with sera
available, terminal RVNA titers were detected from five
Table 1
Results of rabies virus titration with 15 captive-bred naïve raccoons (Procyon lotor).
Raccoon ID Sex Age Trial Virus Dose (log 10 MICLD50) Baseline RVNA (IU/ml) Result (incubation period) Terminal RVNA (IU/ml)
1-007 F A 1 6.9 <0.1 D (15) <0.1
3-800 F A 1 6.9 <0.1 D (10) <0.1
1-600 M A 1 6.9 <0.1 D (12) 0.1
8-342 M A 1 6.9 <0.1 D (11) n.d.a
3-515 M J 1 6.9 <0.1 D (10) 0.2
7-618 F A 1 5.9 <0.1 S <0.1
1-786 M A 1 5.9 <0.1 D (12) <0.1
7-298 M A 1 5.9 <0.1 D (11) 0.3
3-115 M J 1 5.9 <0.1 D (11) 0.5
0-840 M J 1 5.9 <0.1 D (12) <0.1
9-269 F A 2 5.9 <0.1 S <0.1
4-378 F A 2 5.9 <0.1 D (13) 0.3
9-566 F J 2 5.9 <0.1 D (12) <0.1
6-074 F J 2 5.9 <0.1 D (10) <0.1
9-108 F J 2 5.9 <0.1 D (12) <0.1
F = female, M = male, A = adult, J = juvenile, MICLD50 = mouse intracerebral lethal doses, RVNA = rabies virus neutralizing antibodies, D = succumbed and tested rabies
positive, S = survived 90 days and tested rabies negative.
a n.d. = not determined; the animal was found dead during health checks, and terminal blood collection was unsuccessful.
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(0.1–0.5 IU/mL), whereas the remaining seven were seronegative.
The median dose of the two tested (106.2 MICLD50) during the ini-
tial titration was selected for the first vaccine efficacy trial.
Observation of an inadequate prevented fraction during the first
efficacy trial was the rationale for lowering the dose to 105.9
MICLD50 for the second efficacy trial.
3.2. Bait trials
Overall, 92% (46/50) of raccoons interacted with the ULBs and
punctured the blister pack or consumed the bait in its entirety.
Raccoons exhibited slightly higher interaction scores with sham
compared to live ULBs (Table 2), and bait treatment was a mar-
ginal predictor of interaction scores (F = 2.8, p = 0.10) in the mul-
tivariable generalized linear model. Animals in the second trial
exhibited higher interaction scores compared to the first trial
(F = 17.0, p = 0.0002). Spillage of the sham or live vaccine liquid
was noted in 66% (33/50) of the individual bait offerings, whereas
no spillage was observed in 26% (13/50) and not applicable in 8%
Table 2
The mean (standard error) bait interaction score by trial and bait treatment for 50
captive-bred raccoons (Procyon lotor) offered Ontario Rabies Vaccine Baits (ONRAB).
Interactions were scored on a scale of 0 to 4, with increasing integer values for animal
approach, oral manipulation, puncture and consumption behaviors.
Trial Treatment N Mean Score
1 vaccinate 15 2.80 (0.24)
1 sham 6 3.33 (0.21)
Subtotal 21 2.95 (0.19)
2 vaccinate 23 3.87 (0.07)
2 sham 6 4.00 (0.00)
Subtotal 29 3.90 (0.06)
Table 3
Results of immunogenicity and efficacy experiments evaluating delivery of Ontario Rabies Vaccine Baits (ONRAB) across two consecutive trials with 46 captive-bred naïve
raccoons (Procyon lotor). Immunogenicity was measured by quantitation of rabies virus neutralizing antibodies (RVNA) post-vaccination. Efficacy was measured by challenge of
raccoons with a lethal dose of rabies virus 180 days post-vaccination.
Trial ID Sex Agea Treatment RVNA (IU/mL) Terminal Fate
Day 0 Day 30 Day 60 Day 90 Day 176 Day 195 Day 270
1 4-297 F A sham <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 D (13)
1 2-883 M A sham <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 D (13)
1 6-308 M A sham <0.1 <0.1 <0.1 <0.1 <0.1 0.2 D (10)
1 6-864 M A sham <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 D (11)
1 7-838 M A sham <0.1 <0.1 <0.1 <0.1 <0.1 n.d.b D (13)
1 5-788 M J sham <0.1 <0.1 <0.1 <0.1 <0.1 0.2 D (11)
2 3-337 F A sham <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 D (13)
2 0-785 F A sham <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 D (12)
2 1-844 F A sham <0.1 <0.1 <0.1 <0.1 <0.1 n.d. D (14)
2 9-797 F A sham <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 D (12)
2 4-096 M A sham <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 D (11)
2 5-591 M J sham <0.1 <0.1 <0.1 <0.1 <0.1 0.1 D (11)
1 7-363 F A vac <0.1 0.1 0.1 1.1 0.1 74 D (11)
1 7-123 F A vac <0.1 <0.1 <0.1 <0.1 <0.1 22 D (11)
1 4-611 F A vac <0.1 0.1 <0.1 0.1 <0.1 6.6 D (11)
2 7-565 M A vac <0.1 <0.1 <0.1 <0.1 <0.1 1.9 D (12)
2 2-370 M A vac <0.1 <0.1 <0.1 <0.1 <0.1 24 D (14)
1 0-032 M A vac <0.1 2.7 16.5 5.5 0.7 8.5 0.9 S
2 0-553 F A vac <0.1 <0.1 0.2 0.1 <0.1 0.7 <0.1 S
2 1-278 F A vac <0.1 3.6 3.7 3.0 2.5 4.4 2.2 S
2 5-863 F A vac <0.1 0.2 0.9 1.0 0.5 88 13.1 S
2 9-854 F A vac <0.1 1.0 0.2 0.6 0.3 11.1 0.6 S
2 0-823 M A vac <0.1 <0.1 0.3 0.2 0.1 4.2 0.4 S
2 1-382 M J vac <0.1 2.2 2.2 0.7 3.4 3.8 1.1 S
2 9-534 M A vac <0.1 1.5 0.7 0.2 0.1 11.1 1.3 S
2 0-109 M A vac <0.1 0.2 0.2 0.2 0.1 11.1 1.1 S
2 2-066 M A vac <0.1 0.2 0.5 1.5 0.2 44 3.3 S
2 2-285 M A vac <0.1 1.3 0.4 0.6 0.2 7.1 1.3 S
2 4-270 F A vac <0.1 0.7 0.4 1.0 0.2 37 3.5 S
2 7-343 M A vac <0.1 0.1 0.2 0.2 0.2 2.5 0.2 S
2 5-795 F A vac <0.1 0.5 7.5 11.5 5.0 59 16 S
2 9-026 F J vac <0.1 1.5 3.0 2.2 1.7 14.9 0.6 S
2 2-622 F J vac <0.1 3.0 3.7 3.4 3.2 27 5.5 S
2 1-524 F J vac <0.1 2.5 7.0 3.7 1.0 10.0 0.7 S
2 6-839 F J vac <0.1 6.6 8.0 12 10 28 1.2 S
2 7-117 F J vac <0.1 1.0 4.2 3.5 0.7 10.0 2.6 S
2 7-036 F J vac <0.1 3.4 6.6 6.2 3.4 24 4.0 S
2 6-527 F J vac <0.1 2.0 1.0 1.7 0.3 10.0 1.0 S
2 3-773 F J vac <0.1 3.2 3.5 3.2 0.9 13.0 3.3 S
1 6-526 F J vac <0.1 0.8 0.9 2.7 0.2 4.1 21 S
1 8-789 M J vac <0.1 1.1 4.3 3.7 3.4 16 1.8 S
1 5-577 M J vac <0.1 0.8 3.9 4.3 3 21 4.5 S
1 1-572 M J vac <0.1 0.1 0.1 <0.1 <0.1 3.4 <0.1 S
1 8-780 M J vac <0.1 0.9 3.7 3.5 4.4 20 4.4 S
1 9-633 M J vac <0.1 0.8 1.1 0.5 0.5 5.4 0.8 S
1 2-291 M J vac <0.1 4.7 11.5 3.3 4.4 17 5.9 S
F = female, M = male, A = adult, J = juvenile, sham = placebo vaccine bait, vac = live vaccine bait, RVNA = rabies virus neutralizing antibodies, D = succumbed and tested rabies
positive, S = survived 90 days and tested rabies negative.
a Juveniles in cohort 1 were approximately 10 months of age at vaccination, juveniles in cohort 2 were approximately 6 months of age at vaccination.
b n.d. = not determined; the animal was found dead during health checks, and terminal blood collection was unsuccessful.
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(4/50). Among the 33 cases of spillage, a volume of less than
0.1 mL was estimated in all but one case, where an estimate of
0.5 mL was noted. Neither animal age (F = 0.01, p = 0.92) nor
sex (F = 1.5, p = 0.23) were associated with higher bait interaction
scores.
3.3. Vaccine immunogenicity and efficacy
Four raccoons (one adult male, one adult female, two juvenile
males) which had been assigned live vaccine baits in the first trial
were removed from the efficacy test because they neither inter-
acted with nor punctured the blister pack of the ULBs during the
24 h trial. No adverse reactions were noted pv during the observa-
tion period prior to challenge. The RVNA GMT of vaccinated rac-
coons remained equal to or above 0.5 IU/mL during all pv time
points prior to challenge, and the RVBA GMT remained equal to
or above 0.646 EU/mL. Peak antibody response among vaccinated
animals prior to challenge was observed at day 60 pv (RVNA
GMT = 0.9 IU/mL, RVBA GMT = 0.786 EU/mL). Among sham-
vaccinated animals, neither RVNA nor RVBA were detected at any
time point prior to challenge (Tables 3 and 4). The RVNA and RVBA
GMTs of juvenile vaccinates were higher than adults at all pv time
points prior to challenge (Fig. 1, Table S1).
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.vaccine.2018.06.
052.
Mortality to RABV infection among sham-vaccinated raccoons
was 100% (12/12). The prevented fractions among vaccinates were
0.73 (8/11, 95% CI 0.39–0.94) in first (spring) trial and 0.91 (21/23,
95% CI 0.72–0.99) in the second (fall) trial. The incubation period
of animals that developed rabies was 10–14 days (median of
12 days) (Table 3). Heterogeneity in survival curves of adult and
juvenile raccoons was detected between sham and vaccine bait
treatments (adults v2 = 11.3, p = 0.005, juveniles v2 = 16.2,
p = 0.0003; Fig. 2). Heterogeneity in survival curves between juve-
nile and adult vaccinates was not detected (v2 = 1.4, p = 0.80).
Table 4
Rabies virus binding antibody (RVBA) titers, as measured by Bio-Rad Platelia assay, associated with Ontario Rabies Vaccine Bait (ONRAB) vaccination and lethal rabies virus
challenge of 46 captive-bred naïve raccoons (Procyon lotor).
Trial ID Sex Agea Treatment RVBA (EU/mL) Terminal
Day 0 Day 30 Day 60 Day 90 Day 176 Day 195 Day 270
1 4-297 F A sham 0.125 0.125 0.125 0.125 0.125 n.d.
1 2-883 M A sham n.d.b 0.125 0.125 0.125 0.125 n.d.
1 6-308 M A sham 0.125 0.125 0.125 0.125 0.125 n.d.
1 6-864 M A sham n.d. n.d. 0.125 0.125 0.125 n.d.
1 7-838 M A sham 0.125 n.d. 0.125 0.125 0.125 n.d.
1 5-788 M J sham n.d. 0.125 0.125 0.125 0.125 n.d.
2 3-337 F A sham 0.125 0.125 0.125 0.125 0.125 n.d.
2 0-785 F A sham 0.125 0.125 0.125 0.125 0.125 n.d.
2 1-844 F A sham 0.125 0.125 0.125 0.125 0.125 n.d.
2 9-797 F A sham 0.125 0.125 0.125 0.125 0.125 n.d.
2 4-096 M A sham 0.125 0.125 0.125 0.125 0.125 n.d.
2 5-591 M J sham 0.125 0.125 0.125 0.125 0.125 n.d.
1 7-363 F A vac 0.125 0.156 0.125 0.546 0.125 n.d.
1 7-123 F A vac 0.125 n.d. 0.125 0.125 0.125 n.d.
1 4-611 F A vac 0.125 n.d. 0.369 0.228 0.226 n.d.
2 7-565 M A vac 0.125 0.125 0.125 0.125 0.125 n.d.
2 2-370 M A vac 0.125 0.125 0.125 0.125 0.125 n.d.
1 0-032 M A vac 0.133 n.d. 8.350 2.005 0.125 n.d. 1.753
2 0-553 F A vac 0.125 0.138 0.267 0.145 0.151 1.895 0.135
2 1-278 F A vac 0.125 3.959 3.515 3.798 2.333 2.138 2.179
2 5-863 F A vac 0.125 0.125 0.425 0.535 0.125 >20.00 3.434
2 9-854 F A vac 0.125 0.594 0.681 0.245 0.152 6.722 0.464
2 0-823 M A vac 0.125 n.d. 0.845 0.329 0.207 4.488 0.670
2 1-382 M J vac 0.125 1.240 1.671 1.361 1.170 9.137 1.819
2 9-534 M A vac 0.125 1.251 0.599 0.180 0.125 7.770 1.393
2 0-109 M A vac 0.125 n.d. 0.229 0.139 0.125 12.109 1.997
2 2-066 M A vac 0.125 0.496 0.560 n.d. 0.125 >20.00 2.589
2 2-285 M A vac 0.125 0.159 0.244 0.198 0.125 2.483 0.909
2 4-270 F A vac 0.125 0.587 0.234 0.266 0.125 15.554 1.602
2 7-343 M A vac 0.125 n.d. 0.125 0.125 0.125 1.080 0.125
2 5-795 F A vac 0.125 0.990 6.938 3.106 2.907 >20.00 17.649
2 9-026 F J vac 0.125 0.745 1.767 1.650 0.834 7.536 0.529
2 2-622 F J vac 0.125 3.709 2.285 1.920 1.039 >20.00 3.274
2 1-524 F J vac 0.125 1.875 4.610 3.758 0.591 6.106 0.578
2 6-839 F J vac 0.125 4.878 9.132 7.549 5.531 >20.00 0.555
2 7-117 F J vac 0.125 1.007 1.451 1.427 1.140 6.542 2.514
2 7-036 F J vac 0.125 3.202 4.328 3.581 1.967 >20.00 3.722
2 6-527 F J vac 0.125 0.707 1.217 1.281 0.175 8.264 1.572
2 3-773 F J vac 0.125 1.494 1.786 1.848 0.906 11.657 2.362
1 6-526 F J vac 0.125 0.680 1.082 0.941 0.308 2.333 13.900
1 8-789 M J vac 0.125 0.877 3.708 2.787 1.554 >20.00 2.845
1 5-577 M J vac 0.125 0.568 3.291 2.281 1.268 11.992 2.195
1 1-572 M J vac 0.125 n.d. 0.125 0.125 0.125 1.192 0.125
1 8-780 M J vac 0.125 1.384 1.880 2.178 0.125 9.191 1.899
1 9-633 M J vac 0.125 n.d. 0.817 0.546 0.125 3.857 1.479
1 2-291 M J vac 0.125 n.d. 2.756 2.251 0.125 n.d. 2.459
F = female, M = male, A = adult, J = juvenile, sham = placebo vaccine bait, vac = live vaccine bait, RVBA = rabies virus binding antibodies.
a juveniles in cohort 1 were approximately 10 months of age at vaccination, juveniles in cohort 2 were approximately 6 months of age at vaccination.
b n.d. = not determined.
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Terminal blood samples were obtained from ten of 12 sham-
vaccinated raccoons and weak RVNA titers were observed in three
(0.1–0.2 IU/mL), whereas the seven remaining control raccoons
were seronegative. The terminal sera of these ten control animals
were not tested for RVBA. However, among 25 raccoon sera with
RVNA values of 0.1–0.2 IU/mL, and tested by both assays, approx-
imately half (13) were RVBA negative.
A total of five vaccinated raccoons developed rabies, all adults
(Table 3, Fig. 2). Three of these raccoons (7-123, 7-565, 2-370)
never seroconverted pv for RVNA nor RVBA, yet presented terminal
RVNA titers (1.9, 22, and 24 IU/mL respectively). Two of the three
had partially eaten baits, whereas the other had fully consumed
the bait. One vaccinated female (4-611) that fully consumed a bait
and succumbed demonstrated an RVNA titer of 0.1 IU/ml on day 30
and day 90 pv, but was seronegative at other time points, yet pre-
sented a terminal RVNA titer of 6.6 IU/mL. The same animal
demonstrated positive RVBA values on days 60, 90, and 176 pv
(0.369, 0.228, and 0.226 EU/mL respectively). Only one vaccinated
female (7-363) that partially consumed a bait and succumbed
demonstrated an RVNA response up to 1.1 IU/mL on Day 90 pv,
with levels of 0.1 IU/mL at other time points, and a terminal titer
of 74 IU/mL. The same animal demonstrated positive RVBA values
on days 30 and 90 pv (0.156 and 0.546 EU/mL respectively), but
was seronegative on days 60 and 176 pv.
All other 29 vaccinated raccoons mounted RVNA responses
prior to challenge and survived challenge, including all juveniles.
Fig. 1. The (a) geometric mean rabies virus neutralizing antibody (RVNA) and (b) rabies virus binding antibody (RVBA) titers of vaccinated raccoons pre- and post-infection.
Vaccinates included 19 adult (black) and 15 juvenile (gray) raccoons. Error bars reflect the 95% confidence limits on age specific geometric mean titers.
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Four of 29 vaccinated survivors (1-572, 0-553, 0-109, 7-343) were
weak RVNA responders (equal to or less than 0.2 IU/mL across all
time points pv) and two were seronegative prior to challenge,
yet all demonstrated an anamnestic response on day 15 pi (RVNA
0.7–11.1 IU/mL). Two of the four (7-343, 1-572) were RVBA
negative across all time points pv until day 15pi (1.080 and
1.192 EU/mL), and then seronegative upon terminal sampling.
The other two (0-109, 0-553) demonstrated RVBA across multiple
time points pv (range 0.139–0.267 EU/mL), anamnestic responses
on day 15 pi (12.109 and 1.895 EU/mL respectively) and were
RVBA positive at terminal sampling (1.997 and 0.135 EU/mL
respectively).
Even though it was inadequate to protect against lethal RABV
infection, there did appear to be a level of immune priming con-
ferred by vaccination among raccoons which ultimately developed
rabies, as all presented evidence of an anamnestic response at ter-
minal sampling and with RVNA titers that were notably higher
than control animals.
4. Discussion
The control of RABV circulation in raccoons, and other wildlife,
is principally achieved using ORV. To date, existing ORV products
have effectively halted appreciable westward spread of raccoon
RABV in the US, but suboptimal levels of herd immunity in rac-
coons may be insufficient for RABV elimination [5,17]. Novel ORV
products for target wildlife may be needed in the US, and our study
provides evidence of acceptable efficacy among raccoons for one
candidate product. The prevented fractions observed, 0.73 in first
trial and 0.91 in second trial, are comparable to or higher than an
earlier study evaluating the same product in raccoons. Brown
et al. [10] observed 75% survival among vaccinated raccoons com-
pared to 89% mortality among control animals, for a prevented
fraction of 0.72 when animals were challenged with RABV 350
days pv. It is unclear whether the prevented fractions observed
in our study would have been lower under an extended interval
between vaccination and challenge. We reduced the challenge
dose between the first and second trial of the current study, yet
the mortality of sham-vaccinated control animals for both trials
was 100%. The higher dose of challenge virus may have negatively
impacted the prevented fraction observed in the first trial,
although bait interaction scores were also lower.
In the Brown et al [10] study, 100% of 42 wild-caught raccoons
that were offered ONRAB baits punctured the blister pack and/or
consumed the entire bait, compared to 92% (46/50) of captive-
bred raccoons in our study. Collectively, these data indicate high
acceptability of the ONRAB baits by raccoons, similar to what
was observed with other ORV products [18]. In our study, higher
interaction with baits was observed during the trial in mid-
November compared to mid-March; there may be unidentified
seasonal cues that influence attractiveness of ORV baits to free-
ranging raccoons. One controlled field study examining ONRAB
bait visitation and removal by free-ranging raccoons demonstrated
higher bait contact rates in the fall (October) when compared to
late spring (June) and summer (August) [19]. The timing of ORV
targeting raccoons typically occurs in the late summer and early
fall, and so we expect field acceptability to be more similar to
the second trial of our study.
Brown et al [10] did not observe a marked difference in the
immunogenicity of the baits between adult and juvenile cohorts,
in contrast to our results. Nevertheless, both studies collectively
indicate that neither immunogenicity nor efficacy of ONRAB ULB
for juvenile raccoons is inferior compared to adults, which is criti-
cal given the importance of targeting susceptible young of the year
during annual baiting campaigns. Peak antibody response at day 60
pv in this study appears delayed in comparison to prior ONRAB
studies in striped skunks [14] and raccoons [10], although the lat-
ter study reported a peak response at day 56 pv among raccoons
receiving partial vaccine doses. In contrast, timing shifts of peak
antibody response were not evident among striped skunks receiv-
ing different doses of vaccine by direct instillation [14].
A prior study reported a strong non-linear correlation (R2 = 0.8)
of ELISA and RFFIT values across raccoon sera tested in this study,
but a poor correlation (R2 = 0.3) considering the subset with RFFIT
values equal to or less than 1.0 IU/mL [20]. Some of the RVNA titers
reported in this study as weak (0.1–0.2 IU/mL) could be false pos-
itives, given our estimate that half of such samples tested negative
for RVBA. We observed two vaccinates with weak RVNA and RVBA
responses which succumbed to challenge, and two other vacci-
nates with weak RVNA and RVBA below detection limits that sur-
vived challenge. Nevertheless, mean vaccinate RVNA and RVBA
kinetics in this study were remarkably similar and anamnestic
responses to challenge were routinely observed among vaccinates,
even those which succumbed to rabies. The phenomenon of
anamnestic response among oral vaccinates that ultimately suc-
cumb to RABV challenge was observed in earlier studies with
striped skunks [14], raccoons [10,18], and red foxes [21].
The efficacy of ONRAB ULB for raccoons in our second trial was
within recommended prevented fraction standards for animal
rabies vaccines in the US (9 CFR 113.312). These data complement
experimental field trials that have also demonstrated the potential
of ONRAB for the control and prevention of RABV circulation in
free-ranging raccoon populations in the US [17,22].
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